Clinical impact of chromosomal aberrations in multiple myeloma (Q37821077)

23 August 2017

1 reference

title

Clinical impact of chromosomal aberrations in multiple myeloma (English)

1 reference

23 August 2017

H Nahi

1

1 reference

23 August 2017

T Sutlu

2

1 reference

23 August 2017

M Jansson

3

1 reference

23 August 2017

E Alici

4

1 reference

23 August 2017

G Gahrton

5

1 reference

23 August 2017

language of work or name

English

0 references

publication date

15 December 2010

1 reference

Journal of Internal Medicine

23 August 2017

1 reference

23 August 2017

269

1 reference

23 August 2017

2

1 reference

23 August 2017

137-147

1 reference

Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders

23 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Myeloma aetiology and epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Using genomics to identify high-risk myeloma after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

When protein destruction runs amok, malignancy is on the loose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Prognostic significance of copy-number alterations in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Regulation of p53 downstream genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Hematopoietic stem cell transplantation for multiple myeloma beyond 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2010.02324.X

10.1111/J.1365-2796.2010.02324.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference